Author: Sidarta-Oliveira, D.; Poblete Jara, C.; Ferruzzi, A. J.; Skaf, M. S.; Velander, W. H.; Araujo, E. P.; Velloso, L. A.
Title: Assembly of an integrated human lung cell atlas reveals that SARS-CoV-2 receptor is co-expressed with key elements of the kinin-kallikrein, renin-angiotensin and coagulation systems in alveolar cells Cord-id: fk0ri80v Document date: 2020_6_4
ID: fk0ri80v
Snippet: SARS-CoV-2, the pathogenic agent of COVID-19, employs angiotensin converting enzyme-2 (ACE2) as its cell entry receptor. Clinical data reveal that in severe COVID-19, SARS-CoV-2 infects the lung, leading to a frequently lethal triad of respiratory insufficiency, acute cardiovascular failure, and coagulopathy. Physiologically, ACE2 plays a role in the regulation of three systems that could potentially be involved in the pathogenesis of severe COVID-19: the kinin-kallikrein system, resulting in ac
Document: SARS-CoV-2, the pathogenic agent of COVID-19, employs angiotensin converting enzyme-2 (ACE2) as its cell entry receptor. Clinical data reveal that in severe COVID-19, SARS-CoV-2 infects the lung, leading to a frequently lethal triad of respiratory insufficiency, acute cardiovascular failure, and coagulopathy. Physiologically, ACE2 plays a role in the regulation of three systems that could potentially be involved in the pathogenesis of severe COVID-19: the kinin-kallikrein system, resulting in acute lung inflammatory edema; the renin-angiotensin system, promoting cardiovascular instability; and the coagulation system, leading to thromboembolism. Here we analyzed ~130,000 human lung single-cell transcriptomes and show that key elements of the kinin-kallikrein, renin-angiotensin and coagulation systems are co-expressed with ACE2 in alveolar cells, which could explain how changes in ACE2 promoted by SARS-CoV-2 cell entry result in the development of the three most severe clinical components of COVID-19.
Search related documents:
Co phrase search for related documents- abnormal function and lung inflammation: 1
- abnormal regulation and ace enzyme: 1
- ace enzyme and acute cardiovascular failure: 1
- ace enzyme and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8
- ace enzyme and lung inflammatory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- ace inhibitor and lung inflammation: 1
- ace inhibitor and lung inflammatory: 1, 2
- acute cardiovascular failure and lung inflammatory: 1
- acute lung inflammation and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- acute lung inflammation and lung inflammatory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- lps induce and lung inflammation: 1, 2, 3, 4, 5, 6
- lps induce and lung inflammatory: 1, 2, 3, 4, 5, 6, 7
Co phrase search for related documents, hyperlinks ordered by date